| abstract |
The pharmaceutical composition of oral delivery can comprise Bcl-2 family protein Inhibitor, such as, ABT-263, heavy-sulfur family antioxidant and substantially non-aqueous lipidic carrier, wherein said compound and described antioxidant are in the carrier in dissolved state.Said composition is suitable for the oral disease that to need its experimenter to be used for the treatment of with the overexpression of one or more anti-apoptotics Bcl-2 race albumen be feature, such as cancer. |